Biocon up 3% as EMA accepts application for cancer drug

Shital Jibhe / 01 Dec 2017

Biocon up 3% as EMA accepts application for cancer drug

The share prices of Biocon surged over 3 per cent intraday on Friday after the company announced that the European Medicines Agency (EMA) accepted the marketing authorization application for its breast cancer and chemotherapy drug.

The share prices of Biocon surged over 3 per cent intraday on Friday after the company announced that the European Medicines Agency (EMA) accepted the marketing authorization application for its breast cancer and chemotherapy drug. 

At 09:17 hours, the share of Biocon was quoting at Rs. 445.45 per share, up Rs. 13.20 or 3.05 per cent, on the BSE. It touched a 52-week high of Rs. 447.45.

 EMA acceptance of the submission follows an earlier withdrawal of the application by the company in response to an audit of Biocon’s facility conducted by the European authority. 

The company states that it has completed corrective actions outlined as a result of observations and these will be confirmed during the re-inspection of the plant.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.